Silverback Therapeutics Aktie News

Fintel reports that Tanimoto Sarina has filed a 13D form with the SEC disclosing ownership of 6,265,170 shares of Silverback Therapeutics Inc (SBTX).

NEW ORLEANS , Aug. 10, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

NEW YORK , July 27, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Silverback Therapeutics, Inc. (SBTX), relat...

NEW YORK , July 22, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX), in connection with the Company's proposed merger with ARS Pharmaceuticals, Inc. ("ARS").  Under the terms of the merger agreement, assuming that the Company's...

Less than two years after its IPO and months after shutting down its once-promising oncology program, Seattle-based Silverback Therapeutics will merge with another biotech company, San-Diego based ARS Pharmaceuticals.

Silverback Therapeutics will lay off 27% of its workforce and close its oncology program, the Seattle company announced Thursday in its fourth quarter earnings report.

NEW YORK, Jan. 3, 2022 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons and entities that purchased or otherwise acquired: (a) Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX) common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about Decemb...

LOS ANGELES, Dec. 31, 2021 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Silverback Therapeutics, Inc. ("Silverback" or "the Company") (NASDAQ: SBTX) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public of...